Buglaw
Active member
- Joined
- Jun 20, 2022
- Messages
- 79
- Reason
- DX MND
- Diagnosis
- 10/2022
- Country
- US
- State
- IL
- City
- Chicago
I just wanted to flag that there have been a couple of somewhat promising phase 2 trial results that came out this week for various subsets of ALS patients.
The NP-001 is particularly interesting as it showed a significant slowdown in disease progression for individuals with mildly elevated c-reactive protein, including 40% of participants who more or less did not progress for the 6 month study.
ALS Disease Progression Slowed With Low-dose Aldesleukin: Trial |...
A low dose of aldesleukin slowed disease progression and significantly improved survival in ALS patients with less aggressive disease.
alsnewstoday.com
Macrophage-Targeted Sodium Chlorite (NP001) Slows Progression of Amyotrophic Lateral Sclerosis (ALS) through Regulation of Microbial Translocation
Amyotrophic lateral sclerosis (ALS) is a heterogeneous, progressive, and universally fatal neurodegenerative disease. A subset of ALS patients has measurable plasma levels of lipopolysaccharide (LPS) and C-reactive protein (CRP) consistent with low-grade microbial translocation (MT). Unless...
www.mdpi.com
The NP-001 is particularly interesting as it showed a significant slowdown in disease progression for individuals with mildly elevated c-reactive protein, including 40% of participants who more or less did not progress for the 6 month study.